Chimerix (NASDAQ:CMRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Chimerix (NASDAQ:CMRXFree Report) in a research report sent to investors on Friday, Benzinga reports. The firm currently has a $11.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Chimerix’s Q1 2024 earnings at ($0.21) EPS and Q3 2024 earnings at ($0.23) EPS.

A number of other equities analysts also recently weighed in on CMRX. StockNews.com downgraded Chimerix from a hold rating to a sell rating in a research report on Friday, November 3rd. Wedbush reissued an outperform rating and set a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th.

Check Out Our Latest Stock Report on Chimerix

Chimerix Stock Performance

CMRX opened at $1.18 on Friday. Chimerix has a 52-week low of $0.88 and a 52-week high of $1.65. The firm has a market capitalization of $105.27 million, a PE ratio of -1.28 and a beta of 1.16. The business’s 50-day simple moving average is $1.00 and its 200 day simple moving average is $1.00.

Hedge Funds Weigh In On Chimerix

Institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new position in shares of Chimerix in the first quarter valued at approximately $54,000. Ergoteles LLC acquired a new position in shares of Chimerix in the first quarter valued at approximately $65,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Chimerix in the third quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Chimerix in the first quarter valued at approximately $66,000. Finally, Cetera Investment Advisers acquired a new position in shares of Chimerix in the first quarter valued at approximately $77,000. Institutional investors and hedge funds own 44.17% of the company’s stock.

About Chimerix

(Get Free Report)

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection.

Featured Articles

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.